Arcus Biosciences (RCUS) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xencor (XNCR) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 109.6% versus a loss of 29.2%. Over five years, XNCR leads with a -6.2% price change compared with -66.3% for RCUS. Xencor is the larger company by market cap ($2.50 billion vs $2.25 billion), about 1.1 times the size.
Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -142.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCUS | XNCR |
|---|---|---|
| Share price | $15.62 | $33.26 |
| Market cap | $2.25B | $2.50B |
| 1-day change | -1.01% | -2.21% |
| YTD return | -34.45% | +117.24% |
| 1-year return | -29.16% | +109.58% |
| 5-year return | -66.31% | -6.15% |
| EPS (TTM) | $-3.64 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $247.00M | $125.58M |
| Revenue growth (YoY) | -4.26% | +13.65% |
| Net income (latest FY) | $-353.00M | $-91.92M |
| Operating margin | -156.28% | -141.35% |
| Net margin | -142.91% | -73.20% |
| 52-week high | $31.74 | $40.60 |
| 52-week low | $15.56 | $10.38 |
| Distance from 52-week high | -50.78% | -18.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +162.48% | +27.78% |
| Average volume | 1.85M | 1.54M |
| Shares outstanding | 143.99M | 75.04M |
| Employees | 601 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed RCUS by 138.7 percentage points over the past year.
- Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
- Xencor grew revenue faster in its latest fiscal year (+13.65% vs -4.26%).
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
RCUS vs XNCR FAQ
Which is bigger, Arcus Biosciences or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.25B for Arcus Biosciences (RCUS).
Which stock has performed better over the past year, RCUS or XNCR?
XNCR returned +109.58% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Arcus Biosciences and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.